[Drugs for status epilepticus treatment].
The pharmacokinetics and pharmacodynamics of major antiepileptic agents are presented. The onset of action and the factors leading to extraction across the blood brain barrier are described as well as the mechanism and extent of metabolism, and the main interactions with other drugs. For each class, the dosing scheme and practical issues related to administration are described, based on evidence when available in the literature.
Navarro
V
V
Unité d'épilepsie, département de neurophysiologie clinique, hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France.
Mazoit
J-X
JX
D000927:Anticonvulsants / Q000627:therapeutic use*; D001463:Barbiturates / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D000077287:Levetiracetam; D010672:Phenytoin / Q000627:therapeutic use; D010889:Piracetam / Q000031:analogs & derivatives / Q000627:therapeutic use; D015742:Propofol / Q000627:therapeutic use; D013226:Status Epilepticus / Q000188:drug therapy*; D000077236:Topiramate; D014635:Valproic Acid / Q000627:therapeutic use
D000927:Anticonvulsants; D001463:Barbiturates; D006993:Hypnotics and Sedatives; D000077236:Topiramate; D001569:Benzodiazepines; D005632:Fructose; D000077287:Levetiracetam; D014635:Valproic Acid; D010672:Phenytoin; D015742:Propofol; D010889:Piracetam